Table 2.
Correlations among MLST types, toxin genotypes, and antimicrobial susceptibility patterns of the 186 C. difficile isolates
| Antimicrobial agent |
Total no. (%) of all the isolates (n = 186) | MLST types (no. [%] of non-susceptible isolates) | Analysis resultsb | Toxinotypesc (no. [%] of non-susceptible isolates) | Analysis results | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ST26 (n = 33) | ST35 (n = 21) | ST39 (n = 23) | ST54 (n = 31) | ST152 (n = 21) | Other STsa (n = 57) | χ2 | P value | A+B+ (n = 145) | A−B+ (n = 39) | χ2 | P value | ||
| Clindamycin | 159 (85.5) | 33 (100.0) | 21 (100.0) | 18 (78.3) | 30 (96.8) | 13 (61.9) | 44 (77.2) | F | < 0.001 | 125 (86.2) | 34 (87.2) | 0.02 | 0.875 |
| Erythromycin | 160 (86.0) | 33 (100.0) | 21 (100.0) | 23 (100.0) | 30 (96.8) | 7 (33.3) | 46 (80.7) | F | < 0.001 | 120 (82.8) | 39 (100.0) | 7.78 | 0.005 |
| Fusidic acid | 129 (69.4) | 12 (36.4) | 15 (71.4) | 15 (65.2) | 28 (90.3) | 20 (95.2) | 39 (68.4) | 30.18 | < 0.001 | 102 (70.3) | 27 (69.2) | 0.02 | 0.893 |
| Rifampin | 7 (3.8) | 0 | 0 | 5 (21.7) | 0 | 1 (4.8) | 1 (1.8) | F | 0.001 | 2 (1.4) | 5 (12.8) | 8.09 | 0.004 |
| Levofloxacin | 148 (79.6) | 19 (57.6) | 21 (100.0) | 16 (69.6) | 24 (77.4) | 21 (100.0) | 47 (82.5) | F | < 0.001 | 117 (80.7) | 30 (76.9) | 0.27 | 0.602 |
| Moxifloxacin | 14 (7.5) | 0 | 0 | 6 (26.1) | 0 | 1 (4.8) | 7 (12.3) | F | 0.001 | 3 (2.1) | 11 (28.2) | 29.26 | < 0.001 |
| Gatifloxacin | 14 (7.5) | 0 | 0 | 6 (26.1) | 0 | 1 (4.8) | 7 (12.3) | F | 0.001 | 3 (2.1) | 11 (28.2) | 29.26 | < 0.001 |
| Tetracycline | 17 (9.1) | 0 | 11 (52.4) | 0 | 1 (3.2) | 0 | 5 (8.8) | F | < 0.001 | 13 (9.0) | 4 (10.3) | 0.06 | 0.805 |
| Metronidazole | 0 | 0 | 0 | 0 | 0 | 0 | 0 | N/A | N/A | 0 | 0 | N/A | N/A |
| Vancomycin | 0 | 0 | 0 | 0 | 0 | 0 | 0 | N/A | N/A | 0 | 0 | N/A | N/A |
| PIP-TAZ | 0 | 0 | 0 | 0 | 0 | 0 | 0 | N/A | N/A | 0 | 0 | N/A | N/A |
| Ciprofloxacin | 184 (100.0) | 33 (100.0) | 21 (100.0) | 23 (100.0) | 31 (100.0) | 21 (100.0) | 57 (100.0) | N/A | N/A | 145 (100.0) | 39 (100.0) | N/A | N/A |
| MDR | 166 (89.2) | 33 (100.0) | 21 (100.0) | 21 (91.3) | 30 (96.8) | 15 (71.4) | 46 (80.7) | F | 0.001 | 129 (89.0) | 37 (94.9) | 0.64 | 0.425 |
a: Of two non-toxigenic isolates, one (50.0%) was non-susceptible to erythromycin and levofloxacin; both of them (100.0%) were non-susceptible to ciprofloxacin and susceptible to other antimicrobial agents. None of non-toxigenic MDR isolates were found;
b: F: Fisher's exact test; N/A: data not applicable;
c: Non-toxigenic (A−B−) isolates were not included